Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aceto Corporation
ACET | US
7.21
USD0.17
2.41%
ACET | US
About Aceto Corporation
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
13/03/2026
Close
7.21
Open
6.98
High
7.69
Low
6.98
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessACET | US
Risk
57.0
Sharpe
-0.52
Luna's Score
42/100
Recommendation
Sell
Luna says (ACET | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
60.1%1 month
57.0%3 months
66.2%6 months
75.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.51
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
-1.21
Ent. to rev.
2.14
PEG
0.82
Other Fundamentals
EBITDA
-121.50M
MarketCap
594.11M
MarketCap(USD)
594.11M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-57.91
Short ratio
9.15
Short perc.
5.34
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.45
Range1M
1.70
Range3M
8.59
Volumes: Market Activity
Rel. volume
0.99
Price X volume
1.05M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.21 | - | Cheaper |
| Ent. to Revenue | 2.14 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 0.51 | 13.15 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 66.20 | - | Par |
| Debt to Equity | 0.08 | -1.88 | Expensive |
| Debt to Assets | 0.07 | 0.48 | Cheaper |
| Market Cap | 594.11M | - | Emerging |
